

The Evolution of Biopharmaceuticals: Risk Assessment and Clinical Relevance

SESSION 5: The Future of Dissolution – Beyond Quality Control

<i>Introductions</i>	James Mann, PhD	Principal Scientist In Vitro Product Performance, AstraZeneca
<i>Presenters:</i>	Johannes Moes, PhD Kimberely Raines, PhD Rebecca Moody, PhD Robert Schwabe, PhD	Scientific Director, J&J Innovative Medicine Associate Director of Sciences, OPPQ, OPQ, CDER, FDA Pharmaceutical Scientist, OPQA II, OPQ, CDER, FDA Senior Scientist, Boehringer Ingelheim Pharmaceuticals, Inc